Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
View Patent ↗The present invention provides a method for the treatment or prophylaxis of T-helper type 2 (Th2)-mediated disorders using antagonists of IL-11.
1. A method for the treatment of an inflammatory airway condition in a subject, said method comprising administering to said subject an amount of an antagonist of IL-11 or IL-11Rα.
2. The method of claim 1 wherein the inflammatory airway condition is an inflammatory response in the lungs or pulmonary system.
3. The method of claim 1 wherein the inflammatory airway condition is selected from the group comprising asthma, chronic obstructive pulmonary disease (COPD), rhinitis, and allergies.
4. The method of claim 3 wherein the inflammatory airway condition is asthma.
5. The method of claim 1 wherein the antagonist is selected from the group comprising an IL-11 mutein, an antibody specific for IL-11, an antibody specific for IL-11R and a soluble IL-11Rα.
6. The method of claim 5 wherein the antagonist is an IL-11 mutein.
7. The method of claim 6 wherein the IL-11 mutein comprises an amino acid sequence selected from the group comprising SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4.
8. The method of claim 5 wherein the antagonist is an antibody specific for IL-11- or IL-11Rα.
9. The method of claim 2 wherein the antagonist is selected from the group consisting of an IL-11 mutein, an antibody specific for IL-11, an antibody for IL-11R and a soluble IL-11Rα.
10. The method of claim 3 wherein the antagonist is selected from the group consisting of IL-11 mutein, an antibody specific for IL-11, an antibody specific for IL-11R and a soluble IL-11Rα.
11. The method of claim 4 wherein the antagonist is selected from the group consisting of an IL-11 mutein, an antibody specific for IL-11, an antibody specific for IL-11R and a soluble IL-11Rα.
12. The method of any one of claims 1 - 8 or 9 - 11 wherein the subject is a human.
13. The method of claim 12 wherein the antibody specific for IL-11 is human, humanized or chimeric.
14. The method of any one of claims 1 - 8 or 9 - 11 further comprising the administration of one of more of an anti-inflammatory agent, a bronchodilator and an antibiotic.
15. The method of claim 14 wherein the subject is a human.
16. The method of claim 15 wherein the antibody to IL-11 or IL11Rα is human, humanized or chimeric.